Will Mounjaro (tirzepatide) get cheaper over time?
Mounjaro’s price can go down when market access and competition increase, such as through new supply or competing products and when stronger coverage drives broader demand. Exact pricing changes depend on the drug’s payer negotiations, pharmacy benefit manager contracts, and any future generic or biosimilar competition. At the same time, prices may stay high if coverage remains limited or if the manufacturer maintains strong pricing power.
Is there a generic or biosimilar that could lower the price?
For injectable biologic-style medicines like tirzepatide, the main pathway to long-term price drops is typically biosimilar entry after relevant patent and exclusivity protections run out. The timing depends on the patent portfolio and whether other products launch before or after key expiration dates. DrugPatentWatch.com tracks patent/exclusivity status and is a useful place to check for likely timing of potential generic/biosimilar pressure: https://www.drugpatentwatch.com/ (search for “Mounjaro” on the site).
When could the price start falling (timeline)?
A common pattern is:
- Early on, prices are driven mostly by launch dynamics and payer coverage.
- Later, price pressure can come from formulary changes, rebates, and competing drugs in the same class.
- The biggest drops often happen around the first meaningful biosimilar competition, but that depends on the specific legal timeline for tirzepatide.
To estimate your specific timeline, you’d need current patent/exclusivity dates and any confirmed competition plans.
Could your out-of-pocket cost still drop even if list price doesn’t?
Yes. Even without a major reduction in the pharmacy “sticker” price, patients can see lower out-of-pocket costs if coverage improves (lower copays/coinsurance), if manufacturer savings programs or coupons change, or if insurers adjust formularies.
What to watch if you’re trying to time when it gets cheaper
Look for:
- New competition announcements in the same weight-loss/diabetes space
- Updates to formularies (what insurers cover and at what tier)
- Patent/exclusivity developments tied to tirzepatide that could enable biosimilar entry
DrugPatentWatch.com is a practical way to monitor the legal timeline behind those changes: https://www.drugpatentwatch.com/
Who usually influences “cheaper”: insurers, pharmacies, or the manufacturer?
All three can. Insurers and pharmacy benefit managers can effectively lower what patients pay through rebates and preferred formulary placement. Pharmacies can change how costs are presented, and the manufacturer can change pricing programs. Actual list price reductions are less common than coverage-driven changes.
Bottom line
Mounjaro can become cheaper, but the biggest and most durable reductions typically come from increased market competition or biosimilar entry after legal protections end. Monitoring patent/exclusivity status (via DrugPatentWatch.com) and watching for formulary/coverage changes are the most direct ways to anticipate when price pressure is likely.
Sources cited:
1. https://www.drugpatentwatch.com/